Literature DB >> 7144925

Alpha-Monofluoromethyldopa (MFMD) in combination with L-DOPA Effects on tissue catecholamines and blood pressure in rats.

P Johansson, M Henning.   

Abstract

We have investigated the interaction of alpha-monofluoromethyldopa (MFMD) with the effects of i.p. injected L-DOPA (200 mg.kg-1) on blood pressure and tissue catecholamines in normal and spontaneously hypertensive rats (SHR). MFMD 10 mg.kg-1 (i.p.) effectively antagonizes the L-DOPA induced increase in heart dopamine (DA). This action is also seen after 15 or 50 mg.kg-1. The accumulation of DA in the brain is very much reduced by MFMD 50 mg.kg-1 while after 15 or, especially, 10 mg.kg-1 more DA is formed in the brain than after L-DOPA alone, probably due to the peripheral decarboxylase inhibition which presents more L-DOPA to the brain. We conclude that MFMD 10 mg.kg-1 gives a relatively selective peripheral inhibition of the decarboxylation of L-DOPA and this dose combination was accordingly found to result in a reduction of blood pressure in conscious animals. This hypotensive response to L-DOPA was attenuated after MFMD 15 mg.kg-1 and was absent after MFMD 50 mg.kg-1. Interestingly, the hypotensive effect of L-DOPA after MFMD 10 or 15 mg.kg-1 was more pronounced in SHR.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7144925     DOI: 10.1007/bf00586344

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

Review 1.  Decarboxylase inhibitors.

Authors:  G Bartholini; A Pletscher
Journal:  Pharmacol Ther B       Date:  1975

Review 2.  Studies on the mode of action of alpha-methyldopa.

Authors:  M Henning
Journal:  Acta Physiol Scand Suppl       Date:  1969

3.  Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with alpha-monofluoromethyldopa.

Authors:  M J Jung; M G Palfreyman; J Wagner; P Bey; G Ribereau-Gayon; M Zraïka; J Koch-Weser
Journal:  Life Sci       Date:  1979-03-12       Impact factor: 5.037

4.  Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat.

Authors:  M Henning; A Rubenson
Journal:  J Pharm Pharmacol       Date:  1970-08       Impact factor: 3.765

5.  Central decarboxylation and uptake of L-DOPA.

Authors:  N E Andén; J Engel; A Rubenson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

6.  A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from the same tissue sample using a single column of strongly acidic cation exchange resin.

Authors:  C Atack; T Magnusson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-01

Review 7.  Central sympathetic transmitters and hypertension.

Authors:  M Henning
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

8.  Selective inhibitors of biosynthesis of aminergic neurotransmitters.

Authors:  J Kollonitsch; L M Perkins; A A Patchett; G A Doldouras; S Marburg; D E Duggan; A L Maycock; S D Aster
Journal:  Nature       Date:  1978-08-31       Impact factor: 49.962

9.  Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa.

Authors:  P Bey; M J Jung; J Koch-Weser; M G Palfreyman; A Sjoerdsma; J Wagner; M Zraïka
Journal:  Br J Pharmacol       Date:  1980-12       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.